mRNA-1010 Updated Jun 30
Watch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.
- Pivotal Phase 3 data published in the New England Journal of Medicine (May 7, 2026) showed mRNA-1010 was superior to standard-dose licensed flu vaccines in adults 50+, a clear efficacy win for the mRNA platform beyond COVID (source: NEJM).
- FDA advisory committee (VRBPAC) voted 9-0 unanimously on June 18, 2026 that the vaccine's benefits outweigh risks, a near-necessary precondition for approval, with the FDA historically following such votes in the vast majority of cases (source: FDA catalyst data + Ars Technica).
- If approved by the August 5 PDUFA date, mRNA-1010 would be the first-ever mRNA-based influenza vaccine on the US market, giving Moderna first-mover advantage in a large, recurring annual market dominated by older egg/cell-based technologies (source: Clinical Trials Arena).
- The stock has already rallied over 140% from its 52-week low of $22.28 to ~$71, meaning much of the flu vaccine approval story is already priced in. Mean analyst price target is $44.25, the stock trades well above consensus.
- Analyst consensus is a Hold (19 Hold, 4 Buy, 4 Sell, 3 Strong Sell) with zero upgrades or downgrades in the last 90 days, suggesting Wall Street is not chasing this rally (source: analyst data).
- The FDA's initial Refusal-to-File letter (February 2026) shows the agency had concerns about the submission, though reversed, this signals regulatory risk is non-zero even after a positive AdCom (source: HTR Media / National Law Review).